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Aims Randomized controlled trials (RCTs) have shown that the risk of stroke and venous thromboembolism (VTE) is
increased with hormone replacement therapy (HRT); the effect on coronary heart disease (CHD) remains unclear.
Methods
and results
RCTs of HRT were identiﬁed. Event rates for cerebrovascular disease [stroke, TIA (transient ischaemic attack)], CHD
(myocardial infarction, unstable angina, sudden cardiac death), and VTE (pulmonary embolism, deep vein thrombosis)
were analysed. Sensitivity analyses were performed by type of HRT (mono vs. dual) and subject age. 31 trials (44 113
subjects) were identiﬁed. HRT was associated with increases in stroke (odds ratio, OR, 1.32, 95% conﬁdence
intervals, CI, 1.14–1.53) and VTE (OR 2.05, 95% CI 1.44–2.92). In contrast, CHD events were not increased
(OR 1.02, 95% CI 0.90–1.11). Ordinal analyses conﬁrmed that stroke severity was increased with HRT (OR 1.31,
95% CI 1.12–1.54). Although most trials included older subjects, age did not signiﬁcantly affect risk. The addition
of progesterone to oestrogen doubled the risk of VTE.
Conclusion HRT is associated with an increased risk of stroke, stroke severity, and VTE, but not of CHD events. Although
most trials studied older patients, increased risk was not related to age. Combined HRT increases the risk of VTE
compared with oestrogen monotherapy.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Hormone replacement therapy (HRT), which involves giving sex
steroid hormones in the form of an oestrogen, with or without
progesterone, is regularly used in the treatment of menopausal
symptoms.
1 It is also used in women with premature ovarian
failure, and has also been advocated for the prevention of osteo-
porosis since it reduces fracture risk.
2 In observational studies,
HRT was reported to reduce the risk of arterial vascular
events
3,4 and this led to trials investigating whether HRT could
prevent stroke and coronary heart disease (CHD) events.
Unfortunately, adverse effects of HRT have been proposed,
including a possible increased risk of breast cancer,
5 whilst there
is debate over whether the beneﬁts of protecting bone density
may be lost once treatment is discontinued.
6 Furthermore, HRT
has been shown, in meta-analyses, to increase the risk of stroke
7
and venous thromboembolic disease [including both pulmonary
embolism (PE) and deep vein thrombosis (DVT)].
8,9 However,
the effects of HRT on CHD remains unclear
10 although the
possibility of beneﬁt in younger women (age ,60 years) has
been suggested.
11,12
Both oestrogen and progesterone have shown cytoprotective
properties in laboratory studies
13–15 suggesting that they might
alter the severity as well as frequency of vascular events. Conver-
sion of binary vascular events (e.g. stroke/no stroke) into an ordinal
scale (e.g. fatal stroke/non-fatal stroke/no stroke) allows the effect
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16 This is of practical
clinical value as severity is clearly relevant; it is preferable to
have a non-fatal event than a fatal one, and severity impacts on
quality of life, especially with respect to stroke.
17
In parallel, there are no randomized data comparing the relative
effects of the addition of progesterone with oestrogen (dual-HRT)
vs. oestrogen monotherapy. This reﬂects that trials have chosen to
use dual or monotherapy depending on the presence or absence
of the uterus. However, it is possible to assess the additive
effects of progesterone on thrombotic event rates using indirect
comparison of existing trial data.
18
WehavereviewedsystematicallyalltrialsofHRTassessingeffects
on arterial and venous vascular events including cerebrovascular
events,CHD events, and venousthromboembolism (VTE); analyses
assessed both the frequency and severity of events, and examined
the effect of progesterone on the risk of thrombotic events.
Methods
Selection
Completed and published non-confounded randomized controlled
trials (RCTs) of HRT vs. no HRT (open or placebo-controlled) in
women were included. Trials had to report event rates for one or
more of cerebrovascular disease (CVD), CHD or VTE. Trials were
included if these events were primary outcomes or if it was possible
to accurately ascertain event rates from reported adverse events.
Searching
Potential trials were identiﬁed from searches of The Cochrane Library,
Pubmed, Embase, Medline (to Jan 2008), and previous reviews
7,11,19–22
using combinations of the search terms ‘HRT’, ‘hormone replacement
therapy’, ‘clinical trial’, ‘vascular’, ‘cerebrovascular disease’, ‘CVD’,
‘stroke’, ‘coronary heart disease’, ‘CHD’, ‘ischaemic heart disease’,
‘IHD’, ‘venous thromboemb*’, ‘deep vein thrombosis’, ‘DVT’, ‘pulmo-
nary embolism’, ‘PE’. Abstracts were reviewed to determine if the
study was an eligible controlled trial. The papers were obtained for
suitable studies and assessed to determine whether vascular events
were adequately reported. Further studies were identiﬁed from refer-
ence lists from identiﬁed articles. No unpublished trials were included.
Non-English language publications were excluded.
Quality assessment
Studies were assessed for quality in ﬁve areas: method of randomi-
zation (such as computer randomization, randomization lists, etc.),
blinding, reporting of withdrawals, generation of random numbers,
and concealment of allocation. Trials scored one point for each area
addressed, therefore receiving a score between 0 and 5, with 5
reﬂecting the highest level of quality.
23
Data abstraction
All data were extracted in duplicate, independently by two researchers
(L.J.G. and G.M.S.). Disparities were resolved by P.M.W.B.
Study characteristics
Information on trial size, treatment regimen (oestrogen with or
without progesterone, and type), length of follow-up, and outcome/
adverse events were recorded. Vascular outcome events were
counted (identiﬁed as adverse events in some trials), ideally by
intention-to-treat, including CVD [stroke, TIA (transient ischaemic
attack)], CHD [myocardial infarction (MI), sudden cardiac death,
unstable angina] and venous thromboembolic disease (DVT, PE, cere-
bral venous thrombosis). Coronary interventions such as angioplasty
were not counted in CHD events as these are open to bias.
24
Information on trials of raloxifene, a selective oestrogen receptor
modulator, was collected, but this was only included in the raloxifene
speciﬁc sensitivity analysis (described later) and not in either the
dichotomous or ordinal analyses.
Each outcome event (e.g. stroke, TIA, MI, etc.) was counted separa-
tely and as total outcomes under the pooled headings CVD, CHD and
VTE as mentioned earlier. Trials which explicitly stated that no events
occurred were included in the total number of patients; this will have
reduced the proportion of subjects have an event, but will not have
altered the odds ratios (OR) and 95% conﬁdence intervals (CI).
Where sufﬁcient information was given, events were further categor-
ized by severity (described later). If data were taken from lists of
adverse events rather than tabulations of outcomes, the trial was
only included if it could be determined that adverse events had been
reported for each treatment group. Where it was possible to ascertain
that more than one event of the same category had occurred in a
single subject, only one event was counted (the most severe event,
i.e. fatal rather than non-fatal stroke). Since it was not usually possible
to tell which event occurred ﬁrst, the most severe was chosen. DVT
and PE were counted as separate events but the VTE total represents
the most severe event in a single patient.
Quantitative data synthesis
The effect of HRT on dichotomous outcomes was assessed using the
OR calculated using a random effects model since the trials were
expected to be heterogeneous in their design, patient populations,
and interventions.
Pre-speciﬁed sensitivity analyses were deﬁned to examine any
heterogeneity in trial design, including age group (,60,  60 years),
type of HRT (mono/unopposed oestrogen, dual/opposed), type of
oestrogen (oestradiol, conjugated equine oestrogen, CEE, all trials),
type of oestrogen in monotherapy trials alone, phase of prevention
(primary, secondary), method of administration (oral vs. transdermal),
length of follow-up ( 3 years, .3 years), quality (,5/5, 5/5 only), and
smaller vs. larger trials (.3000, ,3000 subjects). Trials of raloxifene
were only included in the sensitivity analysis assessing the effect of
raloxifene. These analyses were carried out by performing separate
meta-analyses for each of the speciﬁed subgroups to determine an
OR for CVD, CHD, and VTE. Subgroups differed if the 95% CI
around the ORs did not overlap.
In order to analyse the effect of HRT on outcome severity, out-
comes were recoded in an ordered categorical manner where
appropriate data were published:
25 In order to be suitable for this
analysis, trials needed to provide data on the outcome of events, e.g.
fatal vs. non-fatal events or TIA vs. stroke: three-level stroke (fatal
stroke/non-fatal stroke/no stroke); four-level CVD (fatal stroke/
non-fatal stroke/TIA/no stroke); three-level CHD (fatal MI/non-fatal
MI/no MI); four-level CHD (fatal MI/non-fatal MI/unstable angina/no
MI) and three-level PE (fatal PE/non-fatal PE/no PE). Insufﬁcient data
were available to do this for DVT and VTE. These ordinal outcomes
were assessed using ordinal logistic regression with trial as a covariate.
As there are not randomized data directly comparing dual- and
mono-HRT, an indirect comparison was performed, using the
method described by Song et al.
18 The relative effects for dual- and
mono-HRT for each outcome (CVD, CHD, and VTE), were measured
by calculating ORs and 95% CI. The indirect comparison (the effect of
progesterone in addition to oestrogen) was calculated by adjusting
these by the common contribution of oestrogen.
18
G.M. Sare et al. 2032Statistical heterogeneity was examined using Higgin’s and
Thompson’s
26 I
2-test. Publication bias was examined using Egger’s test.
27
Data were analysed using Stata (version 8) with weighting for size of trial.
Results
Thirty one trials (44 113 patients) using progesterone and/or
oestrogen, and four trials of raloxifene (17 699 patients) were
identiﬁed (see Supplementary material online, Table S1, Figure 1),
these ranging in size from 50 to 16 608 patients (median 222).
The trials comprised 22 in which vascular prevention was
primary, 10 in patients with prior CHD, two in patients with pre-
vious stroke or TIA, and one in patients with VTE. The average
age of the patients varied between 47 and 75 (median 62.7).
Mono-HRT (oestrogen alone) was studied in seven trials, with
various combinations of oestrogen and progesterone studied in
the others. The dose of oestrogen varied (see Supplementary
material online, Table S1), e.g. CEE, 0.3–2.5 mg with the most com-
monly used dose 0.625 mg, oestradiol, transdermal 0.05 mg, oral
1–2.5 mg. Some trials used more than one dose. Follow-up
varied between 16 weeks and 6.8 years (median 2 years). CVD
was reported in 29 studies, CHD in 27 and VTE events in 25.
One hundred and forty one studies were excluded (Figure 1), as
they were either not randomized; because they contained
inadequate data on thrombotic events; were trials of men or
included both men and women and did not present data separa-
tely; or because they were confounded (i.e. the control group
received an active treatment not received by the HRT group).
28
Data quality
TheRCTs varied in their qualityscore
23from2/5to5/5(median4/5).
It was possible to ascertain numbers of subjects with events rather
than absolute event rate (which may include multiple events in one
subject) in 27 trials (3049 conﬁrmed subjects with events out of
4883 total events analysed). There was no evidence for publication
bias for CVD as an outcome (Egger’s test,
27 P ¼ 0.27), or CHD
(Egger’s test, P ¼ 0.50) but there was evidence of publication
bias for VTE (Egger’s test, P ¼ 0.01). Funnel and Forrest plots
are shown in Figures 2 and 3.
Quantitative data synthesis
Table 1 shows the results for all outcomes. The control event rate
is given to provide information on the background risk of each
event; the changes in risk associated with treatment are therefore
quantiﬁable. HRT increased the odds of having any CVD event by
24% (Table 1, Figure 3A), and stroke by a third. Non-fatal stroke was
increased by 28%; both TIA and fatal stroke showed trends to
increased odds of having an event with HRT although the power
of the TIA was limited owing to the limited number of events
(Table 1). No relationship was seen between HRT and CHD
events, including MI (Figure 3B). Those taking HRT had a
two-fold increase in VTE (Figure 3C), this including increases in
DVT (97%) and PE (74%). Taking all outcomes together in a
single analysis, HRT signiﬁcantly increases a person’s odds of
having any thrombotic event by 23%. No statistical heterogeneity
was found for any outcome (Table 1).
Sensitivity analyses
Sensitivity analyses were performed for pre-speciﬁed subgroups
for CVD, CHD, and VTE (Figure 4). The OR for VTE differed
between monotherapy (OR 1.21, 95% CI 0.92–1.59) vs. dual
therapy (OR 2.45, 95% CI 1.91–3.16) such that the 95% CI did
not overlap. There were no other differences for subgroups
Figure 1 Flowchart for inclusion and exclusion of trials of hormone replacement therapy.
Association between HRT and subsequent arterial and venous vascular events 2033including average age ,60 years (nine trials) vs. age  60 years (16
trials), examining primary vs. secondary prevention, mono vs.
dual-HRT (CVD and CHD only), CEE vs. oestradiol (examined
in all trials and in oestrogen monotherapy trials), shorter vs.
longer follow-up, and high vs. lower quality and larger vs. smaller
trials for CVD, CHD, and VTE.
Figure 2 Funnel plots assessing publication bias showing the distribution of odds ratios for trials of cerebrovascular disease, coronary heart
disease and venous thromboembolic disease.
G.M. Sare et al. 2034Severity of events
When assessing ordered categorical data, a statistically signiﬁcant
result was seen for stroke severity assessed as fatal stroke, non-
fatal stroke, and no stroke (Table 2). The OR of 1.31 signiﬁes
that HRT treatment is associated with a shift to increased stroke
severity. Ordinal regression requires the assumption of ‘propor-
tionality of odds’ to be adhered to and this was present in all of
the trials with more than two levels of data (likelihood ratio
test). Non-signiﬁcant trends to increased severity were seen for
stroke-TIA assessed at four levels, and three-level PE; both of
these assessments suffered from limited published data on event
severity thereby restricting the power of these analyses. No signiﬁ-
cant difference was seen for three-level or four-level CHD, and no
data were available for DVT, and VTE.
Indirect comparison of dual- and
mono-hormone replacement therapy
Seventeen trials that examined combined oestrogen and pro-
gesterone therapy and seven trials that examined oestrogen mono-
therapy (see Supplementary material online, Table S1) were
included in this indirect analysis. The remaining trials each used
both combined therapy, usually in non-hysterectomized women,
and oestrogen monotherapy in hysterectomized women. Only
two of these trials report separate ﬁndings for the two groups
and are therefore included in this indirect comparison in addition
to the other trials.
29,30 The results from the indirect comparison
of oestrogen vs. oestrogen plus progesterone are given in
Table 3. The addition of progesterone to oestrogen doubles the
odds of VTE but has no effect on CVD or CHD. These ﬁndings
are supported by the subgroup sensitivity analysis of oestrogen
monotherapy vs. combined HRT (Figure 3).
Discussion
This systematic review extends the ﬁndings of previous trials and
meta-analyses of HRT with the additional of ordinal regression
analysis to assess effect of HRT on severity and an indirect analysis
to examine the contribution of progesterone on top of oestrogen
to vascular risk. It also includes the most recent study, the
‘Women’s International Study of Long Duration Oestrogen after
the Menopause’ (WISDOM) trial.
29 In essence, HRT is associated
Figure 3 Forrest plots of the effect of hormone replacement therapy. Shaded squares represent the weighting of each trial in the analysis:
(A) Cerebrovascular events (including stroke and TIA); (B) coronary heart disease events (including myocardial infarction); (C) venous throm-
boembolism (including pulmonary embolism, deep vein thrombosis and cerebral sinus thrombosis).
Association between HRT and subsequent arterial and venous vascular events 2035Figure 3 Continued.
G.M. Sare et al. 2036with increased CVD, stroke, and stroke severity, VTE, and its com-
ponents DVT and PE. In contrast, CHD rates are not increased.
The addition of progesterone in dual therapy doubles the risk of
VTE over oestrogen alone.
HRT was found to increase the rate of total CVD by a quarter.
Ordering the severity of stroke by vital status (fatal stroke/non-
fatal stroke/no stroke) allowed ordinal meta-analysis to be per-
formed; HRT increased stroke severity by a third. Since the
assumption of proportionality of odds was adhered to in all of
the trials reporting more than two levels (and trials which do
not adhere to this would tend to attenuate any treatment
effect), this ﬁnding of increased severity is likely to be real. This
ﬁnding of increased severity is supported by a trend to more
fatal strokes in patients receiving HRT using standard dichotomous
analysis (although this analysis is underpowered because of the
limited number of events). Sensitivity analyses did not reveal any
modulating effects on the relationship between HRT and CVD;
importantly, the ﬁndings do not appear to be driven by lower
quality trials.
The ﬁnding that HRT increases VTE extends previous reviews
based on fewer trials.
8,22 HRT appears to double the risk of VTE
and one of its components, DVT, and increase PE by three-
quarters. Ordinal analysis revealed that HRT might more than
double the severity of PE although this ﬁnding was not signiﬁcant
due to the paucity of trials reporting PE by vital status. Subgroup
analysis of type of HRT (mono vs. dual) was signiﬁcantly different
with VTE; dual-HRT signiﬁcantly increases the risk of VTE com-
pared with oestrogen monotherapy. This ﬁnding is supported by
the indirect analysis, which demonstrated a doubling of the risk
of VTE events with the addition of progesterone to oestrogen.
Egger’s test for VTE was signiﬁcant suggesting publication bias.
However, this ﬁnding is likely to be explained by the difference
in effect with monotherapy vs. dual-HRT.
In contrast to its effects on stroke and VTE, HRT did not alter
either beneﬁcially or adversely the rate of CHD events, including
MI. Data on .1600 events occurring in .43000 subjects were
present so the neutral ﬁnding is unlikely to reﬂect inadequate
statistical power. Similarly, ordinal analysis did not suggest that
the severity of CHD events was altered. Sensitivity analysis did
not reveal any signiﬁcant difference in the magnitude of hazard
with any subgroup.
The neutral effect of HRT on CHD events has been noted in the
large WHI trials
31,32 and in previous meta-analyses
12 and our
extended analysis (including the increased power of ordinal
analysis
16) replicates this ﬁnding. This is in contrast to previous
observational studies,
3 which have demonstrated protective
effects of HRT on CHD events. Various hypotheses have been
suggested to explain this conﬂicting ﬁnding, including: differing
effects of HRT on the vascular endothelium with advancing age
(conferring beneﬁts of HRT near the menopause);
33,34 the effect
of higher doses of HRT (increased coagulation activity and vascular
remodelling);
35 detrimental effects of CEE on insulin resistance
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Table 1 Effect of hormone replacement therapy on arterial and venous events (cerebrovascular disease, coronary heart
disease and venous thromboembolism and their constituent parts); with odds ratio (95% conﬁdence intervals) using
random effects model
Trials Subjects Events Control event rate
(events per person/year)
Odds ratio (95%
conﬁdence interval)
P-value Heterogeneity
P
Cerebrovascular
disease
26 43 549 1034 0.02 1.24 (1.09–1.41) 0.001 0.53
Stroke 18 36 523 741 0.02 1.32 (1.14–1.53) ,0.0001 0.87
Transient ischaemic
attack
7 6035 153 0.03 1.05 (0.76–1.45) 0.78 0.53
Fatal stroke 11 32 935 105 0.003 1.35 (0.89–2.03) 0.16 0.39
Non-fatal stroke 10 32 680 581 0.02 1.28 (1.08–1.52) 0.004 0.58
Coronary heart
disease
25 43 159 1636 0.04 1.00 (0.90–1.11) 0.97 0.56
Myocardial
infarction
(MI)
21 41 849 1238 0.03 1.02 (0.91–1.15) 0.70 0.78
Fatal MI 15 40 319 396 0.01 1.03 (0.84–1.26) 0.77 0.49
Non-fatal MI 15 40 319 846 0.02 1.02 (0.88–1.18) 0.77 0.41
Unstable angina 5 9413 360 0.04 0.97 (0.71–1.40) 0.98 0.23
Venous
thromboembolism
22 42 381 547 0.02 2.05 (1.44–2.92) ,0.0001 0.07
Deep vein
thrombosis
16 40 417 376 0.01 1.97 (1.58–2.46) ,0.0001 0.58
Pulmonary
embolism
12 39 612 230 0.004 1.74 (1.32–2.30) ,0.0001 0.66
All thrombotic events 31 44 113 3217 0.08 1.23 (1.07–1.41) 0.004 0.06
Association between HRT and subsequent arterial and venous vascular events 2037Figure 4 Tabulated results of pre-speciﬁed sensitivity analysis for cerebrovascular disease, coronary heart disease, and venous thromboembolism. Odds ratios and 95% conﬁdence intervals are
plotted on a log scale with no effect at 0.
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8(not seen with oestradiol);
36 oral vs. transdermal administration;
36
and detrimental effects of some forms of progesterone.
37,38 In the
present analysis of these hypotheses have, where possible, been
addressed using subgroup analysis.
Of note, CHD events were not signiﬁcantly reduced in younger
women (OR 0.63, 95% CI 0.23–1.77, P ¼ 0.38) in contrast to a
previous analysis (reported OR 0.68, 95% CI 0.48–0.94 in
women ,60 years).
12 Although the point estimates are similar,
the CI and P-values differ considerably. We explored three
points that may explain this difference in ﬁndings. First, the
authors used a ﬁxed effects model for meta-analysis which
assumes that any underlying treatment effect will be the same
across trials; however, this assumption is unlikely to be correct
since HRT trials are heterogeneous in nature (different types of
HRT, mono/dual therapy, different baseline characteristics and
follow-up times) and it is more appropriate to use the more con-
servative random effects model (as used here) which allows for
such variation in trial design. However, this alone does not
explain the signiﬁcant CI seen; performing the present analysis
with a ﬁxed effects model in women ,60 reveals OR 0.62 95%
CI 0.23–1.64, the OR being very close to the analysis using the
random effects model. Secondly, the previous meta-analysis used
data from the large WHI trials divided by age .60 and ,60
years. However, this divided data are a secondary post-hoc analysis
of the WHI, and the primary analysis, which uses all the data as a
whole, is used in the present analysis. A recent analysis of the WHI
data examines the effect of age and time from menopause on vas-
cular events.
39 This shows a non-signiﬁcant trend towards reduced
CHD in both younger women, and with reduced time from meno-
pause. Taking this data into account in our analysis (and noting dif-
fering deﬁnitions of CHD) the risk of CHD in patients (60 years
remains non-signiﬁcant, with a point estimate nearer neutral, OR
0.90 (CI 0.64–1.27). Thirdly, they deﬁned CHD events as MI and
cardiac causes of death which may have included heart failure, an
outcome that is unlikely to be inﬂuenced by HRT and less likely
to occur in younger women, and one not counted in the
present analysis.
The ﬁnding that younger women do not beneﬁt from HRT was
also shown in a recent observational study.
40 One problem in
assessing response by age is that few papers provide information
on time between menopause and recruitment; previous studies
used a cut in age at 60,
12,32 although this is arbitrary. Using
another cut at 55 years does not greatly alter the ﬁndings (OR
0.69, 95% CI 0.19–2.57) and the recent WHI analysis showed
age and time from menopause to be well correlated.
39
Subgroup analyses showed no difference in CHD events by type
of oestrogen (CEE vs. oestradiol) with and without progesterone,
or oral vs. transdermal administration (although the number of
trials using transdermal administration was small). The diverse
dosing regiments precluded meaningful analysis of the effect of
dose of HRT.
In comparison with other meta-analyses
22 we have counted the
number of patients with at least one event rather than the total
number of events. This is important as many patients suffer
more than one event during the course of a trial (i.e. a patient
with a non-fatal stroke may go on to have a fatal stroke) and the
...............................................................................................................................................................................
Table 2 Effect of hormone replacement therapy on the severity of arterial and venous events; by ordinal logistic
regression
Outcome Trials Subjects Ordinal outcome Odds ratio 95% Conﬁdence
interval
P-value
Three-level cerebrovascular disease (fatal stroke/
non-fatal/no stroke)
10 32 679 104/581/31 997 1.31 1.12–1.54 0.001
Four-level cerebrovascular disease (fatal stroke/
non-fatalstroke/TIA/no stroke)
4 12 440 57/291/159/11 933 1.10 0.91–1.33 0.34
Three-level coronary heart disease (fatal MI/non-fatal
MI/no MI)
15 40 252 396/846/39 010 1.04 0.93–1.17 0.49
Four-level coronary heart disease (fatal MI/non-fatal
MI/unstable angina/no MI)
5 7765 140/248/360/7017 1.00 0.85–1.17 0.96
Three-level pulmonary embolism (fatal PE/non-fatal
PE/no PE)
3 7527 4/13/7510 2.57 0.73–9.01 0.14
...............................................................................................................................................................................
Table 3 Indirect comparison of dual (combined oestrogen and progesterone) vs. mono (oestrogen only) hormone
therapy on arterial and venous events (odds ratios shown represent the contribution of progesterone to the risk of
cerebrovascular disease, coronary heart disease and venous thromboembolism in addition to oestrogen therapy)
Outcome Trials oestrogen/oestrogen 1 progesterone Odds ratio 95% Conﬁdence interval
Cerebrovascular disease 8/14 0.93 0.70–1.22
Coronary heart disease 7/16 1.16 0.85–1.53
Venous thromboembolism 6/12 2.02 1.39–2.92
Association between HRT and subsequent arterial and venous vascular events 2039present approach may provide a more accurate estimate of the risk
associated with HRT to an individual.
Several caveats should be made about the present study. First,
data from heterogeneous trials have been aggregated, for example,
duration and type of HRT. This is unlikely to have altered the
results materially since most data came from modern large trials
(e.g. WHI, WISDOM) involving tens of thousands of patients and
the impact of data from older smaller trials will have been small. Sec-
ondly, sensitivity analyses did not reveal any differences in hazard
between different types of intervention, participant, or trial design.
Lastly, several of the analyses had limited power since trial authors
did not report uniformly the effect of HRT on stroke, MI, and VTE,
or on the outcome after these events. It is vital that future trial
reports give such data.
This analysis provides robust information on the relative risks of
arterial and venous vascular events and can be used to help inform
the physician and patient. Any increased risk should be taken
within the context of the underlying absolute risk for each
individual patient, including consideration of other risk factors for
vascular disease, and the possible beneﬁts of treatment.
In summary, HRT is associated with increased rates and severity
of CVD, and increased VTE. The addition of progesterone to oes-
trogen doubles the risk of VTE. In contrast, HRT does not appear
to alter CHD events, including MI. Taking account of the other
negative effects of HRT, HRT cannot be recommended for long-
term vascular prophylaxis in most subjects. This does not affect
current advice on using HRT during the peri-menopausal period
or in women with premature ovarian failure.
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The above article uses a new reference style being piloted by the
EHJ that shall soon be used for all articles.
Association between HRT and subsequent arterial and venous vascular events 2041